

Nathan Robinson

PARTNER

Corporate
Salt Lake City

nrobinson@wsgr.com
801-401-8536

FOCUS AREAS

Capital Markets
Corporate
Corporate Governance
Emerging Companies
Mergers & Acquisitions

EXPERIENCE

Nathan Robinson is a partner in the Salt Lake City office of Wilson Sonsini Goodrich & Rosati, where he specializes in corporate and securities law, including general corporate representation, public offerings, private placements, and mergers and acquisitions. He has significant experience in counseling publicly held companies on disclosure matters and complex securities laws issues. He regularly works with emerging growth, technology, and life sciences companies, both public and private, as well as investment banks, venture capital funds, and private equity firms.

Prior to joining the firm, Nathan practiced in the corporate group at Latham & Watkins and was Sr. Director of Legal, Securities at Lucid Software Inc. In addition to his legal practice, Nathan enjoys teaching law and business school students and most recently taught a course on structuring, negotiating, and drafting transaction agreements at the University of Texas School of Law as an adjunct faculty member during 2019 and 2021.

Prior to law school, Nathan was a consultant with The Gallup Organization.

CREDENTIALS

Education

- J.D., University of Texas School of Law, 2009
- M.B.A., University of Utah, 2004
- B.A., International Studies, Brigham Young University, 2001

Admissions

- State Bar of California
- State Bar of Massachusetts
- State Bar of Texas
- State Bar of Utah

MATTERS

Select Matters

Life Science Sector

- Represented the issuer for the initial public offering of Recursion Pharmaceuticals
- Represented the issuer for the initial public offering of Kinnate Biopharma Inc.
- Represented the underwriters for the initial public offering of the ordinary shares of a medical device company
- Represented Lumos Pharma in its reverse merger with NewLink Genetics Corporation and listing on Nasdaq, at-the-market offerings, and Exchange Act reporting matters

- Represented Savara in underwritten follow-on offerings, at-the-market offerings, PIPEs, and Exchange Act reporting matters
- Represented BioCardia in its Nasdaq uplisting, public offering of common stock and warrants, registered direct offerings, at-the-market offering, equity line of credit offering, and Exchange Act reporting matters
- Represented a public medical device company in the sale of its scope business
- Represented the underwriters in a follow-on public offering of common stock of a biotechnology company focused on neurologic- and endocrine-related disorders
- Represented a specialty pharmaceutical company commercializing proprietary branded prescription drugs in a follow-on public offering of its common stock
- Assisted a public biotechnology company in Exchange Act reporting matters
- Represented Stingray Therapeutics in its Series Seed Preferred Stock financing
- Represented Stingray Therapeutics in its convertible note financing
- Represented the investor in a Series A Preferred Stock investment in Keystone Bio
- Represented the investor in a Series A Preferred Stock investment in Abrexa Pharmaceuticals
- Represented a specialty pharmaceutical company developing immunotherapies for cancer treatment in its Series A preferred stock financing
- Represented a specialty pharmaceutical company developing drugs for respiratory therapies in its Series A preferred stock financing
- Represented a specialty pharmaceutical company developing a needle free patch for pain medication in its Series A preferred stock financing
- Represented a specialty pharmaceutical company developing cancer treatment drugs in its Series A preferred stock financing

Software/Technology Sector

- Represented the issuer for the direct listing of Roblox Corporation
- Represented the underwriters for the initial public offering of C3.ai Inc.
- Represented the issuer for the initial public offering of trivago N.V.
- Represented the underwriters for the initial public offering on Nasdaq Copenhagen of a Danish payment processing company
- Represented RealPage in follow-on equity offerings and convertible debt offering
- Represented the underwriters for convertible debt offerings of Okta
- Represented the underwriters for Q2 Holdings follow-on equity and convertible debt offerings
- Represented National Instruments Corporation in its acquisition of Israel-based Optimal Plus
- Represented National Instruments Corporation in its investment in Monodrive
- Represented National Instruments Corporation in the disposition of AWR Corporation, its subsidiary
- Represented BigCommerce in its acquisition of Feedonomics
- Represented Icon Technologies in its Series Seed preferred stock financing
- Represented Secturion Systems in its Series A and B preferred stock financings
- Represented Conversable, Inc. in its sale to LivePerson
- Represented a global payment processing company in its preferred stock financing
- Represented a software company that developed a software asset management platform in the sale of a large minority interest to a private equity firm
- Represented a private equity firm in its acquisition of a healthcare software solutions company
- Represented a private equity firm in its acquisition of a company providing software to facilitate forms completion, data collection, and process workflow